Rebecca Chambers is the Chief Financial Officer of Veracyte, Inc. since July 2021. Her journey in finance started with a B.S. from John Carroll University followed by an M.B.A. from Cornell University, which laid a solid foundation for her career....

Rebecca Chambers is the Chief Financial Officer of Veracyte, Inc. since July 2021. Her journey in finance started with a B.S. from John Carroll University followed by an M.B.A. from Cornell University, which laid a solid foundation for her career. Before coming to Veracyte, she held several key financial roles at other noteworthy companies. She was the Chief Financial Officer at Outset Medical and also worked at Illumina, a leader in genetic tools, where she handled financial planning and investor relations. With a diverse background across various companies including Myriad Genetics and Millennium Pharmaceuticals, she brings a wealth of experience to her current role. Notably, she leads the CLIA Operations team at Veracyte, focusing on improving efficiency across multiple sites. Chambers has a reputation for achieving corporate goals that relate revenue and cash flows, which reflects her strong financial acumen. Outside of her executive role, she is also a board member at Inari Medical, a company dedicated to tackling venous diseases. In terms of compensation, Chambers is well-aligned with her company’s performance based on revenue growth and cash flow metrics, earning a total of $901,493 in 2023, which includes her salary, bonuses, and other benefits. Her expertise in corporate finance and management is a key asset for Veracyte's success.